Morningstar

BioMarin Pharmaceutical Inc BMRN

Morningstar Rating
Unlock
Stock XNAS Rating as of
$57.18 −1.26 (2.16%)
View Full Chart
As of Delayed Price Post-Trading: $57.30 +0.10

Company Report

View Archive

Narrow-Moat BioMarin's $4.8 Billion Deal for Amicus Therapeutics Expands Rare Disease Portfolio

Rachel Elfman

BioMarin is amassing a portfolio of rare genetic-disease therapies, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development expenses kept BioMarin in the red for years despite multiple approved products, but we're confident in the durable, profit-generating power of its current portfolio. With a deep in-house pipeline and the ability to supplement growth with strategic acquisitions, BioMarin is in a strong position.

Read Analysis

Price vs Fair Value

View History
BMRN is trading at a LOCK|!&h$?sm premium.
Price
$58.44
Fair Value
jbk
Uncertainty
LOCK|CS
1-Star Price
LOCK|p.SZ
5-Star Price
>^^
Economic Moat
LOCK|%Z?C
Capital Allocation
LOCK|jb>wN&?

Bulls Say, Bears Say

Bulls

BioMarin's approved drugs have been granted orphan-drug status in the US and the EU, providing them with at least seven and 10 years of market exclusivity, respectively.

Bears

Diagnosis of very rare genetic diseases can be difficult, and BioMarin could have a hard time locating enough patients to recoup development and manufacturing costs.

Show More

News

View All

Articles & Videos

Trading Information

Previous Close Price
$58.44
Day Range
$57.15–58.73
52-Week Range
$49.26–70.98
Bid/Ask
$57.25 / $68.65
Shares Outstanding
193.57M
Market Cap
$11.07B
Volume/Avg
2M / 2M

Key Statistics

Price/Earnings (Normalized)
21.33
Price/Sales
3.36
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
3,221
Website
https://www.biomarin.com

Competitors

Valuation

View More
Metric
BMRN
SNY
PFE
Price/Earnings (Normalized)
 21.3311.559.22
Price/Book Value
 1.791.351.88
Price/Sales
 3.361.732.53
Price/Cash Flow
 12.497.1510.46
Price/Earnings
BMRN
SNY
PFE

Financial Strength

Metric
BMRN
SNY
PFE
Quick Ratio
 1.160.490.85
Current Ratio
 2.390.991.27
Interest Coverage
 1.948.052.36
Quick Ratio
BMRN
SNY
PFE

Profitability

Metric
BMRN
SNY
PFE
Return on Assets (Normalized)
 5.77%7.96%8.46%
Return on Equity (Normalized)
 8.06%14.96%19.70%
Return on Invested Capital (Normalized)
 6.64%11.28%12.66%
Return on Assets
BMRN
SNY
PFE

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|?Nh?k?rLOCK|^b#d$$128B
 Regeneron Pharmaceuticals Inc
REGN
LOCK|R<^?X^LOCK|&W@v$76B
 Moderna Inc
MRNA
LOCK|M!wT@FZLOCK|&?f$75B
 argenx SE ADR
ARGX
LOCK|%L&<B%ZLOCK|N>@$60B
 BeOne Medicines Ltd ADR
ONC
LOCK|bZwqJgGLOCK|WB$44B
 Alnylam Pharmaceuticals Inc
ALNY
LOCK|$YJ$?JZLOCK|n&$sG$31B
 Royalty Pharma PLC Class A
RPRX
LOCK|@!#$>#gLOCK|&vcnJ$26B
 BioNTech SE ADR
BNTX
LOCK|bKPr@@gLOCK|cw$24B
 Incyte Corp
INCY
LOCK|^@#XqMLOCK|R@$24B
 Jazz Pharmaceuticals PLC
JAZZ
LOCK|HHBNLDLOCK|sd!$15B

Sponsor Center